BioNTech (NASDAQ:BNTX – Get Free Report) had its price objective reduced by equities research analysts at Wells Fargo & Company from $140.00 to $125.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 40.49% from the company’s previous close.
Several other research firms have also weighed in on BNTX. Argus started coverage on shares of BioNTech in a research note on Thursday, October 8th. They set a “hold” rating on the stock. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday, September 16th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Canaccord Genuity Group reduced their price target on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Finally, Bank of America reissued a “buy” rating on shares of BioNTech in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.80.
View Our Latest Analysis on BNTX
BioNTech Trading Up 2.4%
Shares of BioNTech stock traded up $2.06 during trading on Wednesday, hitting $88.97. 281,398 shares of the company were exchanged, compared to its average volume of 1,089,040. The firm has a market capitalization of $22.50 billion, a P/E ratio of -11.36 and a beta of 1.28. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The firm’s fifty day moving average price is $96.14 and its 200 day moving average price is $96.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.
BioNTech (NASDAQ:BNTX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue was down 59.5% compared to the same quarter last year. During the same period last year, the company earned ($1.60) earnings per share. As a group, sell-side analysts expect that BioNTech will post -6.62 earnings per share for the current fiscal year.
Insider Activity at BioNTech
In other news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer owned 36,209 shares in the company, valued at $3,453,252.33. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock worth $79,246,837 over the last quarter. Company insiders own 19.20% of the company’s stock.
Institutional Trading of BioNTech
A number of large investors have recently bought and sold shares of the business. Flossbach Von Storch SE bought a new stake in shares of BioNTech during the second quarter worth $207,142,000. Bank of America Corp DE lifted its position in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares in the last quarter. First Trust Advisors LP lifted its position in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in BioNTech by 79.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after acquiring an additional 337,412 shares in the last quarter. Finally, Candriam S.C.A. boosted its stake in BioNTech by 4.7% in the 3rd quarter. Candriam S.C.A. now owns 520,972 shares of the company’s stock worth $51,399,000 after purchasing an additional 23,442 shares during the period. 15.52% of the stock is owned by institutional investors.
More BioNTech News
Here are the key news stories impacting BioNTech this week:
- Positive Sentiment: BioNTech reported third-quarter revenue of €1.29 billion and EPS of $1.99, both above analyst expectations. It raised its 2026 revenue guidance to €1.7–€1.9 billion, although sales were still down 15% year over year. Article: BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
- Positive Sentiment: Oncology updates offered potential longer-term upside: BioNTech said gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer, and it expects an interim analysis before year-end. The company also reported advancing pumitamig combination trials. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- Neutral Sentiment: BioNTech ended the quarter with €16.2 billion in cash, cash equivalents and investments, providing substantial resources to fund development. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- Negative Sentiment: Risks include lower COVID-19 vaccine demand and a concentrated oncology pipeline. A Seeking Alpha analysis downgraded the stock to Hold, citing cash burn, a narrowing pipeline and reliance on pumitamig and gotistobart; it also questioned whether reported profit reflects underlying cash economics. Article: BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet
About BioNTech
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.
BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.
In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.
Further Reading
- Five stocks we like better than BioNTech
- Advanced Micro Devices’ Q3 Results Answer a Big Question, But Another Remains
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
